Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Pulm Med ; 21(1): 205, 2021 Jun 30.
Article in English | MEDLINE | ID: mdl-34193085

ABSTRACT

BACKGROUND: To assess mortality rate (MR) and standardized mortality rate (SMR) of rheumatoid arthritis-related interstitial lung disease (RA-ILD) patients and to evaluate the role of radiographic patterns in mortality. METHODS: A longitudinal multicentric study was conducted in RA-ILD patients from 2005 to 2015 and followed-up until October 2018 in Madrid. Patients were included in the Neumologia-Reumatología y Enfermedades Autoinmunes Registry, from diagnosis of ILD. The main outcome was all-cause mortality. The radiographic pattern at baseline [usual interstitial pneumonia (UIP), nonspecific interstitial pneumonia (NSIP), or others] was the independent variable. Covariables included sociodemographic and clinical data. Survival techniques were used to estimate MR, expressed per 1000 persons-year with their 95% confidence intervals [CI]. Cox multiple regression model was run to examine the influence of radiographic patterns on survival. SMR [CI] was calculated comparing MR obtained with MR expected in the general population of Madrid by indirect age-gender standardization. RESULTS: 47 patients were included with a follow-up 242 patients-year. There were 16 (34%) deaths, and most frequent causes were acute ILD exacerbation and pneumonia. MR was 64.3 [39.4-104.9], and 50% of the patients died at 8.3 years from ILD diagnosis. After adjusting for confounders, (UIP compared to NSIP was associated with higher mortality risk. The overall SMR was 2.57 [1.4-4.17]. Women of 60-75 years of age were the group with the highest SMR. CONCLUSIONS: RA-ILD is associated with an excess of mortality compared to general population. Our results support that UIP increases the risk of mortality in RA-ILD, regardless other factors.


Subject(s)
Arthritis, Rheumatoid/complications , Lung Diseases, Interstitial/mortality , Lung Diseases, Interstitial/pathology , Aged , Aged, 80 and over , Female , Humans , Longitudinal Studies , Lung Diseases, Interstitial/etiology , Male , Middle Aged , Multivariate Analysis , Spain/epidemiology , Survival Analysis , Tomography, X-Ray Computed
2.
Ann Rheum Dis ; 79(11): 1393-1399, 2020 11.
Article in English | MEDLINE | ID: mdl-32769150

ABSTRACT

OBJECTIVES: To describe patients with autoimmune inflammatory rheumatic diseases (AIRD) who had COVID-19 disease; to compare patients who required hospital admission with those who did not and assess risk factors for hospital admission related to COVID-19. METHODS: An observational longitudinal study was conducted during the pandemic peak of severe acute respiratory syndrome coronavirus 2 (1 March 2020 to 24 April). All patients attended at the rheumatology outpatient clinic of a tertiary hospital in Madrid, Spain with a medical diagnosis of AIRD and with symptomatic COVID-19 were included. The main outcome was hospital admission related to COVID-19. The covariates were sociodemographic, clinical and treatments. We ran a multivariable logistic regression model to assess risk factors for the hospital admission. RESULTS: The study population included 123 patients with AIRD and COVID-19. Of these, 54 patients required hospital admission related to COVID-19. The mean age on admission was 69.7 (15.7) years, and the median time from onset of symptoms to hospital admission was 5 (3-10) days. The median length of stay was 9 (6-14) days. A total of 12 patients died (22%) during admission. Compared with outpatients, the factors independently associated with hospital admission were older age (OR: 1.08; p=0.00) and autoimmune systemic condition (vs chronic inflammatory arthritis) (OR: 3.55; p=0.01). No statistically significant findings for exposure to disease-modifying antirheumatic drugs were found in the final model. CONCLUSION: Our results suggest that age and having a systemic autoimmune condition increased the risk of hospital admission, whereas disease-modifying antirheumatic drugs were not associated with hospital admission.


Subject(s)
Autoimmune Diseases/epidemiology , Coronavirus Infections/therapy , Hospitalization/statistics & numerical data , Pneumonia, Viral/therapy , Rheumatic Diseases/epidemiology , Age Factors , Aged , Aged, 80 and over , Ambulatory Care , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/epidemiology , Autoimmune Diseases/drug therapy , Betacoronavirus , COVID-19 , Diabetes Mellitus/epidemiology , Female , Glucocorticoids/therapeutic use , Heart Diseases/epidemiology , Humans , Hypertension/epidemiology , Length of Stay/statistics & numerical data , Longitudinal Studies , Lung Diseases/epidemiology , Lupus Erythematosus, Systemic/drug therapy , Lupus Erythematosus, Systemic/epidemiology , Male , Middle Aged , Mixed Connective Tissue Disease/drug therapy , Mixed Connective Tissue Disease/epidemiology , Multivariate Analysis , Pandemics , Polymyalgia Rheumatica/drug therapy , Polymyalgia Rheumatica/epidemiology , Protective Factors , Rheumatic Diseases/drug therapy , Risk Factors , SARS-CoV-2 , Sex Factors , Sjogren's Syndrome/drug therapy , Sjogren's Syndrome/epidemiology , Spain/epidemiology , Spondylarthropathies/drug therapy , Spondylarthropathies/epidemiology , Tumor Necrosis Factor Inhibitors/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...